On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Eyes European Growth

  • Located in the Netherlands, Truverra Europe is already established in select European markets, providing an early foothold for Supreme Cannabis
  • Supreme Cannabis’ investment vehicle, Supreme Heights, provides European upstarts with access to capital, proven expertise and tools

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a company dedicated to growing the world’s best cannabis and becoming a leader in the global industry, is creating inroads into Europe’s cannabis industry through its various subsidiaries. The company is taking an aggressive approach to secure its position in Europe’s rapidly increasing cannabis market, a market worth an estimated $318 million in 2018, which is expected to grow more than 400 percent through 2023 (http://ibn.fm/oMWSS). SPRWF subsidiary, Truverra and investment vehicle, Supreme Heights are primed and ready to take advantage of Europe’s rapidly growing cannabis market.

The recently acquired Truverra Inc., a global medicinal CBD brand, provides Supreme Cannabis with additional expansion opportunity in Europe. Truverra’s wholly owned European subsidiary, Truverra Europe, is located in the Netherlands and is already established in select European markets (http://ibn.fm/1VuEV). Truverra uses clean, pure CBD oil drawn from 100 percent organic, European hemp strains. The oil is then combined with natural ingredients to create the exceptional Truverra-branded products that consumers in the United Kingdom have come to expect.

Supreme Cannabis’ London-based investment platform, Supreme Heights (http://ibn.fm/IKsLp), is also penetrating the cannabis market in Europe. The launch of Supreme Heights provided promising European upstarts in the CBD market access to SPRWF’s leadership, comprehension of regulations, premium-product commercialization, marketing, and much more. Patrick Morton, co-founder of Cannabis Invest UK, was made CEO of Supreme Heights, providing the investment platform with his already established, expansive network of local and global cannabis and CBD companies and giving the new platform the jumpstart it needs in collecting potential investments.

In addition, Supreme’s dynamic brand activity has drawn investor attention. The company was recently the subject of an article by CFN Media Group detailing SPRWF’s savvy penetration of the European cannabis market. The article noted that Supreme Cannabis is building its cannabis portfolio at a “blistering pace” and described Europe’s “larger opportunity” for cannabis companies with its population of 513 million people (as compared to only 37 million in Canada). The article added that only five countries of the 28 country members of the European Union ban cannabis.

The CFN analysis (http://ibn.fm/ZMAxt) finds that “nothing speaks more clearly to the ability to scale than Supreme this month providing revenue guidance for the next year in the range of $150 million to $180 million.” The article adds that “the robust growth is owed to management’s ability to make prescient moves to stay in front of regulation changes in addition to operational excellence.” The launch of Supreme Heights provided the company with a gateway to investment in the European cannabis market.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.